{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T06:38:42Z","timestamp":1768459122026,"version":"3.49.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T00:00:00Z","timestamp":1600905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T00:00:00Z","timestamp":1600905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Hepatitis C virus (HCV) infections in people who inject drugs (PWID) can now be treated and cured. However, the impact that HCV treatment has on drug-user health, practices and wellbeing is not known. The aim of this research was to understand the non-clinical impact that HCV treatment has in PWID and their reasons for accessing and completing treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Participants aged 25\u201367\u2009years who had injected opioids or stimulants (currently or in the past) and had completed direct-acting antiviral treatment were recruited from seven European countries. Participants completed a 30-min online survey administered face-to-face between September 2018 and April 2019. The questionnaire responses were used to assess the mental and physical impact of having completed treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of the 124 participants who completed the survey questionnaire, 75% were male, 69% were over 45\u2009years old and 65% were using opioids and\/or stimulants at the start of HCV treatment. Participants reported improvements in the following areas after completing HCV treatment: outlook for the future (79%); self-esteem (73%); ability to plan for the future (69%); belief in their abilities (68%); confidence (67%); empowerment (62%); energy levels (59%); and ability to look after themselves (58%). The most common reasons for starting HCV treatment were: becoming aware of treatments that were well tolerated (77%) and effective (75%); and understanding the potentially severe consequences of HCV (75%).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The benefits of HCV treatment go beyond clinical outcomes and are linked to improved drug-user health and wellbeing. Sharing information about well-tolerated and effective HCV treatments, and raising awareness about the potentially severe consequences of untreated HCV are likely to increase the number of PWID who are motivated to access and complete HCV treatment in future.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-020-05426-4","type":"journal-article","created":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T12:02:47Z","timestamp":1600948967000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Beyond clinical outcomes: the social and healthcare system implications of hepatitis C treatment"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6222-4761","authenticated-orcid":false,"given":"Marta","family":"Torrens","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tokunbo","family":"Soyemi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darcy","family":"Bowman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eberhard","family":"Schatz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,24]]},"reference":[{"key":"5426_CR1","volume-title":"Global hepatitis report","author":"World Health Organization","year":"2017","unstructured":"World Health Organization. Global hepatitis report; 2017. https:\/\/www.who.int\/hepatitis\/publications\/global-hepatitis-report2017\/en. Accessed 28 Aug 2020."},{"issue":"2","key":"5426_CR2","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/hep.22375","volume":"48","author":"H-H Thein","year":"2008","unstructured":"Thein H-H, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology. 2008;48(2):418\u201331.","journal-title":"Hepatology."},{"issue":"6","key":"5426_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-026726","volume":"9","author":"Q Chen","year":"2019","unstructured":"Chen Q, Ayer T, Bethea E, et al. Changes in hepatitis C burden and treatment trends in Europe during the era of direct-acting antivirals: a modelling study. BMJ Open. 2019;9(6):e026726.","journal-title":"BMJ Open"},{"key":"5426_CR4","unstructured":"Olafsson S, L\u00f6ve TJ, Fridriksdottir RH, et al. Mission possible: In Iceland 95% of eligible HCV infected patients were initiated on treatment within three years. Results from the Treatment as Prevention for Hepatitis C (TraP HepC) program. AASLD 2019; Poster #1516."},{"issue":"4","key":"5426_CR5","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/cld.626","volume":"9","author":"J Grebely","year":"2017","unstructured":"Grebely J, Dore GJ. Treatment of HCV in persons who inject drugs: treatment as prevention. Clin Liver Dis (Hoboken). 2017;9(4):77\u201380.","journal-title":"Clin Liver Dis (Hoboken)"},{"issue":"1","key":"5426_CR6","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1111\/add.14393","volume":"114","author":"J Grebely","year":"2019","unstructured":"Grebely J, Larney S, Peacock A, et al. Global, regional, and country-level estimates of hepatitis C infection among people who have recently injected drugs. Addiction. 2019;114(1):150\u201366.","journal-title":"Addiction."},{"key":"5426_CR7","volume-title":"Hepatitis C among drug users in Europe \u2013 epidemiology, treatment and prevention","author":"European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)","year":"2016","unstructured":"European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Hepatitis C among drug users in Europe \u2013 epidemiology, treatment and prevention; 2016. http:\/\/www.emcdda.europa.eu\/system\/files\/publications\/2953\/TDXD16002ENN_final_web.pdf. Accessed 28 Aug 2020."},{"issue":"12","key":"5426_CR8","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.2298\/VSP150511135K","volume":"73","author":"M Kosti\u0107","year":"2016","unstructured":"Kosti\u0107 M, Koci\u0107 B, Tiodorovi\u0107 B. Stigmatization and discrimination of patients with chronic hepatitis C. Vojnosanit Pregl. 2016;73(12):1116\u201324.","journal-title":"Vojnosanit Pregl"},{"key":"5426_CR9","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.drugpo.2018.04.004","volume":"57","author":"CE Paquette","year":"2018","unstructured":"Paquette CE, Syvertsen JL, Pollini RA. Stigma at every turn: health services experiences among people who inject drugs. Int J Drug Policy. 2018;57:104\u201310.","journal-title":"Int J Drug Policy"},{"issue":"5","key":"5426_CR10","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.ijnurstu.2011.11.004","volume":"49","author":"BJ Stewart","year":"2012","unstructured":"Stewart BJ, Mikocka-Walus AA, Harley H, Andrews JM. Help-seeking and coping with psychosocial burden of chronic hepatitis C: a qualitative study of patient, hepatologist, and counsellor perspectives. Int J Nurs Stud. 2012;49(5):560\u20139.","journal-title":"Int J Nurs Stud"},{"issue":"48","key":"5426_CR11","doi-asserted-by":"publisher","first-page":"6928","DOI":"10.3748\/wjg.v25.i48.6928","volume":"25","author":"S Nardelli","year":"2019","unstructured":"Nardelli S, Riggio O, Rosati D, et al. Hepatitis C virus eradication with directly acting antivirals improves health-related quality of life and psychological symptoms. World J Gastroenterol. 2019;25(48):6928\u201338.","journal-title":"World J Gastroenterol"},{"key":"5426_CR12","doi-asserted-by":"publisher","first-page":"107793","DOI":"10.1016\/j.drugalcdep.2019.107793","volume":"207","author":"S Colledge","year":"2020","unstructured":"Colledge S, Larney S, Peacock A, et al. Depression, post-traumatic stress disorder, suicidality and self-harm among people who inject drugs: a systematic review and meta-analysis. Drug Alcohol Depend. 2020;207:107793.","journal-title":"Drug Alcohol Depend"},{"key":"5426_CR13","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.drugalcdep.2015.06.007","volume":"153","author":"AW Batchelder","year":"2015","unstructured":"Batchelder AW, Peyser D, Nahvi S, Arnsten JH, Litwin AH. \u201cHepatitis C treatment turned me around:\u201d psychological and behavioural transformation related to hepatitis C treatment. Drug Alcohol Depend. 2015;153:66\u201371.","journal-title":"Drug Alcohol Depend"},{"issue":"6","key":"5426_CR14","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1038\/ajg.2016.99","volume":"111","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Stepanova M, Henry L, Nader F, Hunt S. An in-depth analysis of patient-reported outcomes in patients with chronic hepatitis C treated with different anti-viral regimens. Am J Gastroenterol. 2016;111(6):808\u201316.","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"5426_CR15","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12888-018-1735-6","volume":"18","author":"I Sundberg","year":"2018","unstructured":"Sundberg I, Lannerg\u00e5rd A, Ramklint M, Cunningham JL. Direct-acting antiviral treatment in real world patients with hepatitis C not associated with psychiatric side effects: a prospective observational study. BMC Psychiatry. 2018;18(1):157.","journal-title":"BMC Psychiatry"},{"issue":"13","key":"5426_CR16","doi-asserted-by":"publisher","first-page":"824","DOI":"10.12968\/bjon.2019.28.13.824","volume":"28","author":"S Montague","year":"2019","unstructured":"Montague S, Agarwal K, Cannon M. Exploring the emotions of patients undergoing therapy for hepatitis C. Br J Nurs. 2019;28(13):824\u20138.","journal-title":"Br J Nurs"},{"issue":"3","key":"5426_CR17","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.jhep.2019.04.016","volume":"71","author":"DM Evon","year":"2019","unstructured":"Evon DM, Sarkar S, Amador J, et al. Patient-reported symptoms during and after direct-acting antiviral therapies for chronic hepatitis C: the PROP UP study. J Hepatol. 2019;71(3):486\u201397.","journal-title":"J Hepatol"},{"issue":"1","key":"5426_CR18","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/liv.13949","volume":"39","author":"E Day","year":"2019","unstructured":"Day E, Hellard M, Treloar C, et al. Hepatitis C elimination among people who inject drugs: challenges and recommendations for action within a health systems framework. Liver Int. 2019;39(1):20\u201330.","journal-title":"Liver Int"},{"key":"5426_CR19","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jsat.2019.01.021","volume":"100","author":"O Falade-Nwulia","year":"2019","unstructured":"Falade-Nwulia O, Irvin R, Merkow A, et al. Barriers and facilitators of hepatitis C treatment uptake among people who inject drugs enrolled in opioid treatment programs in Baltimore. J Subst Abuse Treat. 2019;100:45\u201351.","journal-title":"J Subst Abuse Treat"},{"key":"5426_CR20","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s41124-016-0011-y","volume":"1","author":"JF Dillon","year":"2016","unstructured":"Dillon JF, Lazarus JV, Razavi HA. Urgent action to fight hepatitis C in people who inject drugs in Europe. Hepatol Med Policy. 2016;1:2.","journal-title":"Hepatol Med Policy"},{"key":"5426_CR21","unstructured":"Sperle I, Hedrich D, Palczak K, Singleton N, Zimmermann R. Barriers to HCV testing in drug treatment services for people who inject drugs. INHSU 2018; Poster #161."},{"key":"5426_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0207226","volume":"13","author":"A Madden","year":"2018","unstructured":"Madden A, Hopwood M, Neale J, Treloar C. Beyond interferon side effects: what residual barriers exist to DAA hepatitis C treatment for people who inject drugs? PLoS One. 2018;13:e0207226.","journal-title":"PLoS One"},{"key":"5426_CR23","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12876-015-0320-4","volume":"15","author":"S Zhang","year":"2015","unstructured":"Zhang S, Bastian ND, Griffin PM. Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US. BMC Gastroenterol. 2015;15:98.","journal-title":"BMC Gastroenterol"},{"issue":"Suppl 2","key":"5426_CR24","doi-asserted-by":"publisher","first-page":"S111","DOI":"10.1093\/cid\/cit266","volume":"57","author":"M Schaefer","year":"2013","unstructured":"Schaefer M, Sarkar R, Diez-Quevedo C. Management of Mental Health Problems Prior to and during treatment of hepatitis C virus infection in patients with drug addiction. Clin Infect Dis. 2013;57(Suppl 2):S111\u20137.","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"5426_CR25","doi-asserted-by":"publisher","first-page":"S87","DOI":"10.1016\/j.jhep.2015.02.006","volume":"62","author":"JM Pawlotsky","year":"2015","unstructured":"Pawlotsky JM, Feld JJ, Zeuzem S, Hoofnagle JH. From non-a, non-B hepatitis to hepatitis C virus cure. J Hepatol. 2015;62(Suppl 1):S87\u201399.","journal-title":"J Hepatol"},{"key":"5426_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0216123","volume":"14","author":"I Chikovani","year":"2019","unstructured":"Chikovani I, Ompad DC, Uchaneishvili M, et al. On the way to hepatitis C elimination in the republic of Georgia \u2013barriers and facilitators for people who inject drugs for engaging in the treatment program: a formative qualitative study. PLoS One. 2019;14:e0216123.","journal-title":"PLoS One"},{"key":"5426_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0222186","volume":"14","author":"D Crowley","year":"2019","unstructured":"Crowley D, Cullen W, Lambert JS, Van Hout MC. Competing priorities and second chances \u2013 a qualitative exploration of prisoners' journeys through the hepatitis C continuum of care. PLoS One. 2019;14:e0222186.","journal-title":"PLoS One"},{"issue":"7503","key":"5426_CR28","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/510043a","volume":"510","author":"CM Rice","year":"2014","unstructured":"Rice CM, Saeed M. Hepatitis C: treatment triumphs. Nature. 2014;510(7503):43\u20134.","journal-title":"Nature."},{"key":"5426_CR29","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s41124-018-0033-8","volume":"3","author":"J-M Delile","year":"2018","unstructured":"Delile J-M, de Ledinghen V, Jauffret-Roustide M, et al. Hepatitis C virus prevention and care for drug injectors: the French approach. Hepatol Med Policy. 2018;3:7.","journal-title":"Hepatol Med Policy"},{"issue":"8","key":"5426_CR30","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/j.clinthera.2018.05.010","volume":"40","author":"SN Kapadia","year":"2018","unstructured":"Kapadia SN, Marks KM. Hepatitis C management simplification from test to cure: a framework for primary care providers. Clin Ther. 2018;40(8):1234\u201345.","journal-title":"Clin Ther"},{"issue":"1","key":"5426_CR31","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12954-018-0248-4","volume":"15","author":"A Madden","year":"2018","unstructured":"Madden A, Hopwood M, Neale J, Treloar C. Beyond cure: patient reported outcomes of hepatitis C treatment among people who inject drugs in Australia. Harm Reduct J. 2018;15(1):42.","journal-title":"Harm Reduct J"},{"key":"5426_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/HMER.S187133","volume":"11","author":"C Roncero","year":"2018","unstructured":"Roncero C, Ryan P, Littlewood R, et al. Practical steps to improve chronic hepatitis C treatment in people with opioid use disorder. Hepat Med. 2018;11:1\u201311.","journal-title":"Hepat Med"},{"key":"5426_CR33","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.drugpo.2017.07.022","volume":"47","author":"CW Helsper","year":"2017","unstructured":"Helsper CW, Janssen MP, van Essen GA, et al. Effectiveness and cost-effectiveness of nationwide campaigns for awareness and case finding of hepatitis C targeted at people who inject drugs and the general population in the Netherlands. Int J Drug Policy. 2017;47:117\u201325.","journal-title":"Int J Drug Policy"},{"issue":"Suppl 1: M6","key":"5426_CR34","doi-asserted-by":"publisher","first-page":"104","DOI":"10.2174\/1874220301603010104","volume":"3","author":"A Myles","year":"2016","unstructured":"Myles A. The role of physicians\u2019 attitudes and the provision of hepatitis C virus treatment to people who inject drugs. Open Med J. 2016;3(Suppl 1: M6):104\u201312.","journal-title":"Open Med J"},{"key":"5426_CR35","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/S0140-6736(05)76462-X","volume":"353","author":"M Torrens","year":"1999","unstructured":"Torrens M, Domingo-Salvany A, Alonso J, Castillo C, San L. Methadone and quality of life. Lancet. 1999;353:1101.","journal-title":"Lancet."},{"key":"5426_CR36","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.drugalcdep.2006.06.012","volume":"86","author":"M Pr\u00e9au","year":"2007","unstructured":"Pr\u00e9au M, Protopopescu C, Spire B, et al. Health related quality of life among both current and former injection drug users who are HIV-infected. Drug Alcohol Depend. 2007;86:175\u201382.","journal-title":"Drug Alcohol Depend"},{"key":"5426_CR37","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.drugalcdep.2019.01.037","volume":"198","author":"DL Biancarelli","year":"2019","unstructured":"Biancarelli DL, Biello KB, Childs E, et al. Strategies used by people who inject drugs to avoid stigma in healthcare settings. Drug Alcohol Depend. 2019;198:80\u20136.","journal-title":"Drug Alcohol Depend"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-05426-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-020-05426-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-05426-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T02:10:50Z","timestamp":1632449450000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-020-05426-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,24]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["5426"],"URL":"https:\/\/doi.org\/10.1186\/s12879-020-05426-4","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,24]]},"assertion":[{"value":"3 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Written informed consent was obtained from all survey participants. Given the nature of this market research project, Clinical Research Ethics Committee and\/or Independent Review Board approval was not required, according to the EphMRA code of conduct (Section 1.3). The research team complied with all European laws protecting personal data. To comply with General Data Protection Regulation, data were only collected from the 124 people who completed the survey questionnaire and all responses were anonymised. The research team complied with the ESOMAR, EphMRA, MRS and BHBIA codes of conduct.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from participants for publication of aggregated, anonymised survey responses.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Tokunbo Soyemi and Darcy Bowman are employees of Gilead Sciences Europe Ltd. and may own stock or stock options. Marta Torrens has received consultancy fees from AbbVie, Esteve, Gilead Sciences, Lundbeck, Merck Sharp & Dohme and Servier. The Correlation European Harm Reduction Network receives funding from Gilead Sciences for hepatitis C-related research and activities.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"702"}}